RecruitingPhase 1NCT07536061

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects With Huntington's Disease (INSIGHTT)

Sponsor

Sarepta Therapeutics, Inc.

Enrollment

32 participants

Start Date

May 12, 2026

Study Type

INTERVENTIONAL

Conditions

Huntington’s Disease

Summary

This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).

Eligibility

Min Age: 21 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called SRP-1005 for people with huntington’s disease. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 21 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.